A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?
Publication/Presentation Date
9-22-2020
Abstract
OBJECTIVE: Pancreatic cancer is the most aggressive common cancer and is desperately in need of novel therapies. Unlike many other common cancers, there have been no new paradigm-changing therapies in the past 40 years beyond multi-agent chemotherapy. In this study, we perform the first comprehensive analysis of the current clinical trial landscape in pancreatic cancer to better understand the pipeline of new therapies.
MATERIALS AND METHODS: We queried https://clinicaltrials.gov/ for registered pancreatic cancer clinical trials. Studies were curated and categorized according to phase of study, clinical stage of the study population, type of the intervention under investigation, and biologic mechanism targeted by the therapy under study.
RESULTS: As of May 18, 2019, there were 430 total active therapeutic interventional trials testing 590 interventions. The vast minority of trials (
CONCLUSIONS: A large number of novel therapeutic strategies are currently under investigation. They include a broad range of therapies targeting diverse biologic processes. However, only a small number of novel therapies are in late-stage testing, suggesting that future progress is likely several years away, and dependent on the success of early-stage trials.
Volume
11
Issue
38
First Page
3489
Last Page
3501
ISSN
1949-2553
Published In/Presented At
Katayama, E. S., Hue, J. J., Bajor, D. L., Ocuin, L. M., Ammori, J. B., Hardacre, J. M., & Winter, J. M. (2020). A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike?. Oncotarget, 11(38), 3489–3501. https://doi.org/10.18632/oncotarget.27727
Disciplines
Medicine and Health Sciences
PubMedID
33014285
Department(s)
Department of Surgery, Lehigh Valley Topper Cancer Institute
Document Type
Article
